Click here for slides on this topic


Diabetes mellitus

A disease of carbohydrate, protein, and fat metabolism brought on by relative or absolute insulin deficiency. The disease is characterized by chronic hyperglycemia, which can result in damage to the kidneys, eyes, heart, blood vessels, and other organs. (See type 1 diabetes, type 2 diabetes, gestational diabetes.)


The following content matched the glossary term: Diabetes mellitus

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

Four-year weight losses in the Look AHEAD study: factors associated with long-term success

Top

Alert: October 20, 2012: The Look AHEAD trial has been halted due to futility. Read exclusive commentary from Anne Peters, MD, one of the study’s principal investigators, on the important role of lifestyle interventions for preventing obesity and diabetes despite the lack of CV benefit seen in the trial. Wadden TA, Neiberg RH, Wing RR, et al; for the Look AHEAD Research Group. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity. 2011;19(10):1987-1998. This analysis of 4-year data from the Look AHEAD (Action for Health in Diabetes) trial examined the effect of lifestyle on weight loss and identified demographic characteristics and lifestyle behaviors associated with sustained weight loss in the intensive lifestyle intervention treatment group.

NDEI.org Expert Commentary on Look AHEAD trial Anne Peters

Top

Expert commentary on Look AHEAD trial from Anne Peters, MD.

Look AHEAD Trial Halted—Lifestyle Modifications Fail to Reduce CV Events in Patients With Diabetes  

NDEI.org Expert Commentary ACCORD BP Trial Henry Ginsberg

Top

Expert commentary from Henry Ginsberg, MD on post-hoc analysis of ACCORD BP trial examining the potential interaction between obesity and intensive blood pressure treatment on CVD outcomes.

Type 2 diabetes and cardiovascular disease in women

Top

Norhammar A, Schenck-Gustafsson K. Type 2 diabetes and cardiovascular disease in women. Diabetologia. 2012 Sep 4.Epub ahead of print. Cardiovascular disease is the leading cause of death in both men and women. This is also true for patients with diabetes. In general, differences between the sexes are present in several areas, such as epidemiology, pathophysiology, diagnostics, treatment response and prognosis, as well as the way in which disease is experienced and expressed.

Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults

Top

Neeland IJ, Turer AT, Ayers CR, Powell Wiley TM, Vega GL, Farzaneh Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150-1159. The risk of type 2 diabetes mellitus is heterogeneous among obese individuals. Factors that discriminate prediabetes or diabetes risk within this population have not been well characterized.

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Top

ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585. The blood-pressure (BP) arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study evaluated the effects of intensive BP-control on cardiovascular disease (CVD) events among high-risk subjects with type 2 diabetes.

Ethnic Differences in Weight Loss and Diabetes Remission After Bariatric Surgery: A meta-analysis

Top

Admiraal WM, Celik F, Gerdes VE, Dallal RM, Hoekstra JB, Holleman F. Ethnic Differences in Weight Loss and Diabetes Remission After Bariatric Surgery A meta analysis. Diabetes Care. 2012;35(9):1951-1958. It has been postulated that the effectiveness of bariatric surgery varies between ethnic groups. However, data regarding this topic are inconclusive, as most studies included few patients from minority groups.

Western-style fast food intake and cardiometabolic risk in an eastern country

Top

Odegaard AO, Koh WP, Yuan JM, Gross MD, Pereira MA. Western style fast food intake and cardiometabolic risk in an eastern country. Circulation. 2012;126(2):182-188. BACKGROUND: Western-style fast food contributes to a dietary pattern portending poor cardiometabolic health in the United States. Western-style fast food contributes to a dietary pattern portending poor cardiometabolic health in the United States. With globalization, this way of eating is becoming more common in developing and recently developed populations.

Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk

Top

Guasch-Ferré M, Bulló M, Martínez-González MÁ, Corella D, Estruch R, Covas MI, Arós F, Wärnberg J, Fiol M, Lapetra J, Muñoz MÁ, Serra-Majem L, Pintó X, Babio N, Díaz-López A, Salas-Salvadó J. Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk. PLoS One. 2012;7(8):e43275. Several anthropometric measurements have been associated with cardiovascular disease, type-2 diabetes mellitus and other cardiovascular risk conditions, such as hypertension or metabolic syndrome.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Diabetes mellitus Slides Found: 181
DIGAMI 2: Cumulative Mortality After Acute MI in Type 2 Diabetes
Decreased beta-Cell Function in Groups With Diabetes and at High Risk
LIFE: New-Onset Diabetes
CVD Risk Reduction From Tight Control of BP and Glucose in Type 2 Diabetes
MICRO-HOPE: ACEI Reduces Risk of Nephropathy and CHF in Patients With Type 2 Diabetes
Cardiovascular Impact of Pioglitazone Therapy: A Meta-analysis
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
HEART2D Trial: A1C Values at Each Visit for 60 Months
Survival Functions for the Secondary Macrovascular Endpoint
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
Survival Functions for the Primary Macrovascular Endpoint
Improved Glycemic Control When Adding Metformin to Insulin Therapy
ADVANCE Substudy: Effects of BP Lowering and Intensive Glucose Control on Retinopathy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
LOADD: Nutritional Intervention for Persistent, Treated Hyperglycemia
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Design
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
ORIGIN: Design
BLOOM-DM: Design
BLOOM-DM: Primary and Secondary Endpoints
BLOOM-DM: Subject Profile
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥5% Reduction in Baseline Body Weight
BLOOM-DM Co-Primary Endpoint: Change in Body Weight
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥10% Reduction in Baseline Body Weight
BLOOM-DM: Secondary Endpoints
BLOOM-DM: Adverse Events
Look AHEAD at 4 Years: Weight Reduction
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Design
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
Guidelines for Children and Adolescents With Type 2 Diabetes: Insulin Therapy
Guidelines for Children and Adolescents With Type 2 Diabetes: Lifestyle Changes, Metformin for All
Guidelines for Children and Adolescents With Type 2 Diabetes: A1C Testing
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (2 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Weight Loss, Diet (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Weight Loss, Diet (2 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Physical Activity
Comorbidities in Children and Adolescents With Type 2 Diabetes: Retinopathy
Comorbidities in Children and Adolescents With Type 2 Diabetes: Microalbuminuria
Comorbidities in Children and Adolescents With Type 2 Diabetes: Depression
Comorbidities in Children and Adolescents With Type 2 Diabetes: Obesity-Related Medical Conditions
Comorbidities in Children and Adolescents With Type 2 Diabetes: Hypertension
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (1 of 2)
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (2 of 2)
Type 2 Diabetes Remission in Look AHEAD
Can Coronary Artery Calcium Predict CVD Outcomes in Type 2 Diabetes?
CANTATA-M: Significant A1C Reductions with Canagliflozin Vs Placebo at 26 Weeks
CANTATA-M: Greater Proportion of Subjects Achieved A1C <7.0% with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant FPG Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant Weight Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant Reductions in Systolic BP Seen with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Effect of Canagliflozin Vs Placebo on Lipid Values at 26 Weeks
CANTATA-M: Adverse Events with Canagliflozin Vs Placebo at 26 Weeks
CANTATA-M: Design
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Significantly Better Glycemic Control with Saxagliptin
SAVOR-TIMI 53: Safety Endpoints
SAVOR-TIMI 53: Design
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
AleCardio: Time to First Occurrence of Any Part of the Composite of CV Mortality, Nonfatal MI, or Nonfatal Stroke With Aleglitazar Vs Placebo
AleCardio: Aleglitazar Safety Vs Placebo
AleCardio: Design
SAVOR TIMI Saxagliptin Pancreatitis | NDEI
SAVOR TIMI 53 Pancreatitis Risk Factors Saxagliptin DPP-4 | NDEI
No Pancreatic Cancer Signal Saxagliptin DPP-4 SAVOR TIMI | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Diabetes Pregnancy Guidelines Endocrine Society GDM A1C | NDEI
Managing Diabetes Glucose During Pregnancy Endocrine Society Guidelines | NDEI
Diabetes Pregnancy Guidelines Endocrine Society Glucose Monitoring | NDEI
Diabetes Pregnancy Guidelines Insulin Therapy | NDEI
Diabetes Pregnancy Guidelines Noninsulin Therapy | NDEI
Diabetes Pregnancy Guidelines Preconception Insulin | NDEI
Diabetes Pregnancy Guidelines Preconception Hypertension | NDEI
Diabetes Pregnancy Guidelines Preconception CVD Dyslipidemia | NDEI
Diabetes Pregnancy Guidelines Eye Care Retinopathy | NDEI
Diabetes Pregnancy Guidelines Renal Nephropathy | NDEI
Diabetes Pregnancy Guidelines Preconception Endocrine Society | NDEI
Diabetes Pregnancy Guidelines Diabetes Testing Endocrine Society | NDEI
Diabetes Pregnancy Guidelines GDM Testing Endocrine Society | NDEI
Diabetes Pregnancy Guidelines Nutrition GDM | NDEI
Diabetes Pregnancy Guidelines Weight Management GDM | NDEI
Diabetes Pregnancy Guidelines Postpartum Care GDM | NDEI
Diabetes Pregnancy Guidelines Postpartum Lactation GDM | NDEI
ARIC Cardiovascular Risk Trends | NDEI
Hypertension Obesity Diabetes CVD Risk Factors in ARIC Study | NDEI
CVD Risk Trends ARIC Gender | NDEI
CVD Risk Trends By Race ARIC Study | NDEI
BLOOM-DM Lorcaserin Glycemic Effect Type 2 Diabetes | NDEI
Canagliflozin & Sitagliptin A1C Type 2 Diabetes ENDO2015 PPT | NDEI
AACE 2015 Diabetes Guidelines Glycemic Target A1C PPT | NDEI
AACE 2015 Guidelines Type 2 Diabetes Diagnosis Screening PPT | NDEI
AACE 2015 Guidelines Criteria for Diagnosing Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Prediabetes Diagnosis IFG IGT PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Values Indicating Prediabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Lifestyle Changes Diet Exercise PPT | NDEI
AACE 2015 Diabetes Guidelines Hypoglycemia Management PPT | NDEI
AACE 2015 Diabetes Guidelines Cardiovascular Disease Targets | NDEI
AACE 2015 Guidelines Managing Dyslipidemia in Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
AACE 2015 Guidelines Hypertension Management PPT | NDEI
AACE 2015 Diabetes Guidelines Obesity Management BMI Bariatric | NDEI
AACE 2015 Diabetes Guidelines Nephropathy Management Microvascular | NDEI
AACE 2015 Diabetes Guidelines Retinopathy Management PPT | NDEI
AACE 2015 Diabetes Guidelines Neuropathy Management PPT | NDEI
AACE 2015 Guidelines In-Patient Glycemic Targets Critically Ill A1C | NDEI
AACE 2015 Diabetes Guidelines Treating Hyperglycemia in the Hospital | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring in the Hospital In-Patient | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring CGM SMBG PPT | NDEI
AACE 2015 Diabetes Guidelines Gestational Diabetes Diagnosis PPT | NDEI
AACE 2015 Diabetes Guidelins Glycemic Targets Pregnancy GDM PPT | NDEI
AACE 2015 Guidelines Treating Gestational Diabetes GDM PPT | NDEI
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
AHA ADA Guidelines Diabetes CVD PPT | NDEI
AHA ADA Diabetes Diagnosis Criteria Guidelines PPT | NDEI
Lifestyle Management for CVD Prevention in Diabetes AHA ADA | NDEI
Lifestyle for Weight Loss in Diabetes AHA ADA Guidelines | NDEI
Pharmacologic Therapy for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Bariatric Metabolic Surgery for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Bariatric Surgery for Weight Loss in Type 2 Diabetes for CVD Prevention | NDEI
Individualized Diabetes Therapy for CVD Prevention in Type 2 Diabetes AHA ADA | NDEI
A1C Targets AHA ADA Guidelines Type 2 Diabetes CVD Prevention | NDEI
Type 2 Diabetes & CVD Risk AHA ADA Guidelines PPT | NDEI
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
Aspirin Therapy Type 2 Diabetes CVD Prevention PPT | NDEI
Kidney Disease in Type 2 Diabetes for CVD Prevention PPT | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
Type 2 Diabetes Screening US Preventive Type 2 Diabetes Guidelines | NDEI
Type 2 Diabetes Risk Factors US Preventive Services Guidelines | NDEI
Blood Glucose Values Indicating Prediabetes or Type 2 Diabetes
Type 2 Diabetes Risk Factors Screening US Preventive Guidelines | NDEI
Type 2 Diabetes Diagnostic Criteria US Preventive Guidelines | NDEI
Gestational Diabetes Mellitus (GDM) Diagnosis ADA Guidelines | NDEI PPT
Type 2 Diabetes and Prediabetes Screening for Children ADA Guidelines | NDEI
Diagnosing Gestational Diabetes Mellitus GDM ADA Guidelines | NDEI PPT
Glycemic Targets in Pregnancy ADA Guidelines 2016 | NDEI PPT
Type 2 Diabetes Prevention ADA Guidelines 2016 | NDEI PPT
ADA Guidelines for Gestational Diabetes (GDM) 2016 | NDEI PPT
Postpartum Follow-Up for Women With Gestational Diabetes ADA Guidelines | NDEI
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Rosuvastatin & Incident Type 2 Diabetes | NDEI
JUPITER Insulin Resistance Associated With Risk Factors | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI
SAVOR-TIMI 53 Saxagliptin Not Associated With Fracture Risk Diabetes | NDEI